CRISPR/Cas9 system in breast cancer therapy: advancement, limitations and future scope

Cancer statistics, 2022

(2022) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Dual CRISPR interference and activation for targeted reactivation of X-linked endogenous FOXP3 in human breast cancer cells

(2022) Xuelian Cui et al.   Molecular Cancer

Single-cell long noncoding RNA (lncRNA) transcriptome implicates MALAT1 in triple-negative breast cancer (TNBC) resistance to neoadjuvant chemotherapy

(2021) Hibah Shaath et al.   Cell Death Discovery

Versatile modification of the CRISPR/Cas9 ribonucleoprotein system to facilitate in vivo application

(2021) Bixi Sun et al.   JOURNAL OF CONTROLLED RELEASE

In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy

(2021) Meiou Dai et al.   Nature Communications

RNA-binding protein FXR1 drives cMYC translation by recruiting eIF4F complex to the translation start site

(2021) Jasmine George et al.   Cell Reports

CRISPR/dCas9-Based Systems: Mechanisms and Applications in Plant Sciences

(2021) Chou Khai Soong Karlson et al.   Plants-Basel

Targeting RLIP with CRISPR/Cas9 controls tumor growth

(2020) Jyotsana Singhal et al.   CARCINOGENESIS

Transcriptomic and cellular analyses of CRISPR/Cas9-mediated edition of FASN show inhibition of aggressive characteristics in breast cancer cells

(2020) Fernando Gonzalez-Salinas et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies

(2020) Devikala Gurusamy et al.   CANCER CELL

CRISPR/Cas: From Tumor Gene Editing to T Cell-Based Immunotherapy of Cancer

(2020) Mohammadreza Azangou-Khyavy et al.   Frontiers in Immunology

Identification of preexisting adaptive immunity to Cas9 proteins in humans

(2019) Carsten T. Charlesworth et al.   NATURE MEDICINE

Ultrasound microbubble-mediated CRISPR/Cas9 knockout of C-erbB-2 in HEC-1A cells

(2019) Junhong Cai et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

Impact of CXCR4 and CXCR7 knockout by CRISPR/Cas9 on the function of triple-negative breast cancer cells

(2019) Meng Yang et al.   OncoTargets and Therapy

miR-23b and miR-27b are oncogenic microRNAs in breast cancer: evidence from a CRISPR/Cas9 deletion study

(2019) Bethany N. Hannafon et al.   BMC CANCER

Cdk5 knocking out mediated by CRISPR-Cas9 genome editing for PD-L1 attenuation and enhanced antitumor immunity

(2019) Huan Deng et al.   Acta Pharmaceutica Sinica B

Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers

(2019) Bowen Sun et al.   ONCOGENE

Modeling breast cancer using CRISPR/Cas9-mediated engineering of human breast organoids

(2019) Johanna F Dekkers et al.   JNCI-Journal of the National Cancer Institute

Search-and-replace genome editing without double-strand breaks or donor DNA

(2019) Andrew V. Anzalone et al.   NATURE

Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity

(2019) Guangchuan Wang et al.   NATURE IMMUNOLOGY

miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer

(2019) Deepak Parashar et al.   Cell Reports

Blocking “don't eat me” signal of CD47-SIRPα in hematological malignancies, an in-depth review

(2018) Atlantis Russ et al.   BLOOD REVIEWS

PHF5A Epigenetically Inhibits Apoptosis to Promote Breast Cancer Progression.

(2018) Yi-Zi Zheng et al.   CANCER RESEARCH

Main steps in DNA double-strand break repair: an introduction to homologous recombination and related processes

(2018) Lepakshi Ranjha et al.   CHROMOSOMA

Delivering CRISPR: a review of the challenges and approaches

(2018) Christopher A. Lino et al.   DRUG DELIVERY

Combinatorial CRISPR-Cas9 Metabolic Screens Reveal Critical Redox Control Points Dependent on the KEAP1-NRF2 Regulatory Axis

(2018) Dongxin Zhao et al.   MOLECULAR CELL

Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1

(2018) Yinghua Zhu et al.   Nature Communications

Development of an integrated CRISPRi targeting ΔNp63 for treatment of squamous cell carcinoma

(2018) Masakazu Yoshida et al.   Oncotarget

DNA Unwinding Is the Primary Determinant of CRISPR-Cas9 Activity

(2018) Shanzhong Gong et al.   Cell Reports

Transcriptional Dysregulation of MYC Reveals Common Enhancer-Docking Mechanism

(2018) Jurian Schuijers et al.   Cell Reports

Break Breast Cancer Addiction by CRISPR/Cas9 Genome Editing

(2018) Haitao Yang et al.   Journal of Cancer

Application of the CRISPR/Cas9 System to Drug Resistance in Breast Cancer

(2018) Yinnan Chen et al.   Advanced Science

Combination Immunotherapy: Taking Cancer Vaccines to the Next Level

(2018) Jeremy M. Grenier et al.   Frontiers in Immunology

Exposing cancer with CRISPR-Cas9: from genetic identification to clinical therapy

(2018) Ping Fan et al.   Translational Cancer Research

Strategies for controlling CRISPR/Cas9 off-target effects and biological variations in mammalian genome editing experiments

(2018) Michelle L. Kimberland et al.   JOURNAL OF BIOTECHNOLOGY

TTK promotes mesenchymal signaling via multiple mechanisms in triple negative breast cancer

(2018) Jamie L. King et al.   Oncogenesis

mTOR kinase leads to PTEN-loss-induced cellular senescence by phosphorylating p53

(2018) Seung Hee Jung et al.   ONCOGENE

Delivery systems of CRISPR/Cas9-based cancer gene therapy

(2018) Alessio Biagioni et al.   Journal of Biological Engineering

SG formation relies on eIF4GI-G3BP interaction which is targeted by picornavirus stress antagonists

(2018) Xiaodan Yang et al.   Cell Discovery

Activating PTEN Tumor Suppressor Expression with the CRISPR/dCas9 System

(2018) Colette Moses et al.   Molecular Therapy-Nucleic Acids

Genetic testing in women with breast cancer: implications for treatment

(2017) Robin Paterson et al.   Expert Review of Anticancer Therapy

Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?

(2017) Angela Toss et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Metabolic shifts in residual breast cancer drive tumor recurrence

(2017) Kristina M. Havas et al.   JOURNAL OF CLINICAL INVESTIGATION

In vivo genome editing via the HITI method as a tool for gene therapy

(2017) Keiichiro Suzuki et al.   JOURNAL OF HUMAN GENETICS

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

(2017) Justin Eyquem et al.   NATURE

Identification of essential genes for cancer immunotherapy

(2017) Shashank J. Patel et al.   NATURE

Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening

(2017) Julia Joung et al.   Nature Protocols

Immunity to CRISPR Cas9 and Cas12a therapeutics

(2017) Wei Leong Chew   Wiley Interdisciplinary Reviews-Systems Biology and Medicine

The Chromatin Structure Differentially Impacts High-Specificity CRISPR-Cas9 Nuclease Strategies

(2017) Xiaoyu Chen et al.   Molecular Therapy-Nucleic Acids

The BRCA1- 11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin

(2016) Y. Wang et al.   CANCER RESEARCH

High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects

(2016) Benjamin P. Kleinstiver et al.   NATURE

A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice

(2016) Yang Yang et al.   NATURE BIOTECHNOLOGY

Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer

(2016) A Harrod et al.   ONCOGENE

Sperm-associated antigen 9 (SPAG9) promotes the survival and tumor growth of triple-negative breast cancer cells

(2016) Nirmala Jagadish et al.   TUMOR BIOLOGY

The association of PTEN hypermethylation and breast cancer: a meta-analysis

(2016) Shanshan Luo et al.   OncoTargets and Therapy

CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter

(2016) Samrat Roy Choudhury et al.   Oncotarget

Overcoming doxorubicin resistance of cancer cells by Cas9-mediated gene disruption

(2016) Jong Seong Ha et al.   Scientific Reports

FOXA1 defines cancer cell specificity

(2016) G. Zhang et al.   Science Advances

CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer

(2015) Yubao Wang et al.   CELL

Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy

(2015) M. Giuliano et al.   CLINICAL CANCER RESEARCH

Noninvasive Detection of Activating Estrogen Receptor 1 (ESR1) Mutations in Estrogen Receptor-Positive Metastatic Breast Cancer

(2015) D. S. Guttery et al.   CLINICAL CHEMISTRY

MMEJ-assisted gene knock-in using TALENs and CRISPR-Cas9 with the PITCh systems

(2015) Tetsushi Sakuma et al.   Nature Protocols

High-throughput functional genomics using CRISPR–Cas9

(2015) Ophir Shalem et al.   NATURE REVIEWS GENETICS

CRISPR/Cas9-mediated gene knockout of NANOG and NANOGP8 decreases the malignant potential of prostate cancer cells

(2015) Norihiko Kawamura et al.   Oncotarget

Off-target Effects in CRISPR/Cas9-mediated Genome Engineering

(2015) Xiao-Hui Zhang et al.   Molecular Therapy-Nucleic Acids

Emergence of Constitutively Active Estrogen Receptor-  Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer

(2014) R. Jeselsohn et al.   CLINICAL CANCER RESEARCH

Estrogen Receptor Mutations in Breast Cancer--New Focus on an Old Target

(2014) C. V. Segal et al.   CLINICAL CANCER RESEARCH

Improving CRISPR-Cas nuclease specificity using truncated guide RNAs

(2014) Yanfang Fu et al.   NATURE BIOTECHNOLOGY

A human fatty acid synthase inhibitor binds β-ketoacyl reductase in the keto-substrate site

(2014) Mary Ann Hardwicke et al.   Nature Chemical Biology

Systems level-based RNAi screening by high content analysis identifies UBR5 as a regulator of estrogen receptor-α protein levels and activity

(2014) M J Bolt et al.   ONCOGENE

Microhomology-mediated end-joining-dependent integration of donor DNA in cells and animals using TALENs and CRISPR/Cas9

(2014) Shota Nakade et al.   Nature Communications

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

(2013) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Relative and disease-free survival for breast cancer in relation to subtype: a population-based study

(2013) Pamela Minicozzi et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

DNA targeting specificity of RNA-guided Cas9 nucleases

(2013) Patrick D Hsu et al.   NATURE BIOTECHNOLOGY

Greatwall is essential to prevent mitotic collapse after nuclear envelope breakdown in mammals

(2013) M. Alvarez-Fernandez et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

Chromatin Sampling—An Emerging Perspective on Targeting Polycomb Repressor Proteins

(2013) Robert J. Klose et al.   PLoS Genetics

The CD47–SIRPα pathway in cancer immune evasion and potential therapeutic implications

(2012) Mark P Chao et al.   CURRENT OPINION IN IMMUNOLOGY

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

(2012) Christina Curtis et al.   NATURE

FOXA1: a transcription factor with parallel functions in development and cancer

(2011) Gina M. Bernardo et al.   BIOSCIENCE REPORTS

New drugs for breast cancer subtypes: Targeting driver pathways to overcome resistance

(2011) Giuseppe Curigliano   CANCER TREATMENT REVIEWS

Stem Cell Quiescence

(2011) L. Li et al.   CLINICAL CANCER RESEARCH

Phosphatases: providing safe passage through mitotic exit

(2011) Claudia Wurzenberger et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Antiestrogens and Their Therapeutic Applications in Breast Cancer and Other Diseases

(2010) Simak Ali et al.   Annual Review of Medicine

The Substrate of Greatwall Kinase, Arpp19, Controls Mitosis by Inhibiting Protein Phosphatase 2A

(2010) A. Gharbi-Ayachi et al.   SCIENCE

PTEN/PI3K/Akt Pathway Regulates the Side Population Phenotype and ABCG2 Activity in Glioma Tumor Stem-like Cells

(2009) Anne-Marie Bleau et al.   Cell Stem Cell